Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan

  • Adragos Pharma now third largest pure-play CDMO in the Japanese market
  • Long-term agreement with Sanofi secures local healthcare supply

Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest pure-play contract manufacturer in Japan, one of its three core markets. The acquisition also kicks off a long-term supply agreement between the CDMO and Sanofi. Kawagoe Pharma will continue to produce for Sanofi and the Japanese market as a strategic partner, thus playing an essential role for the local healthcare system.

The official handover of the production facility took place yesterday in the presence of the workforce, which will remain at the site, as well as of representatives of both companies.

The Kawagoe site near Tokyo is one of the largest and most technically advanced of its kind in Japan. Under Sanofi, oral solids and ampoules were manufactured here. In addition, the site provided packaging, visual inspection, and QC test services for the Japanese and Asian markets.

Jeremy Goldnadel, International Cluster Head, Manufacturing and Supply, of Sanofi expressed, "I would like, in the name of Sanofi, to express our deepest gratitude to the highly professional employees at the Kawagoe site over our long 50-years history, and looking forward, wish them all the success and bright future at Adragos Pharma. We are convinced that our long-term partnership will ensure the supply of high quality medicines generating the greatest possible benefit for patients in Japan."

Dr. Andreas Raabe, CEO of Adragos Pharma: "With this acquisition, we have taken an important step towards becoming a leading global CDMO. Our goal is to introduce new customers from Europe, North America and the Japanese domestic market to the production site, as well as to further expand the site's services and capabilities for Sanofi and future customers."

Marco Gorgas, CTO at Adragos Pharma, explains, "The site's capabilities and resources provide a solid foundation for future growth. Both Sanofi and our new customers can rely on our full commitment to providing affordable, high-quality products to patients."

The exact terms of the transaction are not disclosed.

Here you can find images to download for your story. We are grateful for a publication reference.



About Adragos Pharma

Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan (as of March 1, 2023).

Subscribe to releases from Adragos Pharma

Subscribe to all the latest releases from Adragos Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Adragos Pharma

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories20.3.2023 09:14:40 CET | Press release

Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich / London / Athens, March 20th, 2023 - Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers. Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development s

Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan13.10.2022 10:56:33 CEST | Pressemeddelelse

Munich / Paris / Tokyo, October 13, 2022 – Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan. Adragos Pharma will also enter into a long-term supply agreement with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Furthermore, Adragos Pharma will introduce new customers to the manufacturing site from Europe, North America as well as the domestic Japanese market. Their second investment in the region, Adragos Pharma will now rank among the Top 3 largest pure-play CDMOs in Japan. Sanofi and Adragos Pharma signed definitive agreements for the transfer of ownership of one of Sanofi’s manufacturing sites in Japan. The site, located in Kawagoe, Japan, has more than 50 years of pharmaceutical manufacturing history. Under Sanofi, the site ma